United States - English - NLM (National Library of Medicine)

strides pharma science limited - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate oral suspension, usp is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). history of hypersensitivity to megestrol acetate or any component of the formulation. known or suspected pregnancy.

United States - English - NLM (National Library of Medicine)

strides pharma science limited - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - butalbital, acetaminophen and caffeine tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: – hypersensitivity or intolerance to any component of this product – patients with porphyria. barbiturates may be habit-forming: tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. the lethal dose of a barbiturate is far less if alcohol is also ingested. major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. one method involves initiating treatment at the patient's regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - eptifibatide - solution for infusion - 0.75 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - eptifibatide - solution for injection - 2 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - methotrexate - solution for inj/inf - 25 mg/ml

Malta - English - Medicines Authority

strides arcolab international limited - cytarabine 20 mg/ml - solution for infusion or injection

Malta - English - Medicines Authority

strides arcolab international limited - cytarabine 20 mg/ml - solution for infusion or injection

Malta - English - Medicines Authority

strides arcolab international limited - cytarabine 20 mg/ml - solution for infusion or injection

Malta - English - Medicines Authority

strides arcolab international limited - cytarabine 100 mg/ml - solution for infusion or injection

Malta - English - Medicines Authority

strides arcolab international limited - oxaliplatin 5 mg/ml - concentrate for solution for infusion